Open AccessClinicopathological and prognostic role of cyclin D1 in esophageal squamous cell carcinoma: a meta‐analysis
Author(s) -
Zhao J.,
Li L.,
Wei S.,
Gao Y.,
Chen Y.,
Wang G.,
Wu Z.
Publication year - 2012
Publication title -
diseases of the esophagus
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.115
H-Index - 63
eISSN - 1442-2050
pISSN - 1120-8694
DOI - 10.1111/j.1442-2050.2011.01278.x
Subject(s) - medicine , cyclin d1 , confidence interval , immunohistochemistry , hazard ratio , odds ratio , stage (stratigraphy) , oncology , esophageal squamous cell carcinoma , meta analysis , gastroenterology , carcinoma , pathology , cancer , cell cycle , biology , paleontology
SUMMARY Cyclin D1 is one of the most commonly over‐expressed oncogenes; however, its role in esophageal squamous cell carcinoma (ESCC) remains controversial. We conducted a meta‐analysis of 20 studies, comprising 2,041 patients to clarify this issue. In all studies, paraffin‐embedded surgical specimens were collected and the status of cyclin D1 was determined by immunohistochemistry (IHC). The combined odds ratios (Ors) for cyclin D1 expression were 0.74 (95% confidence interval [CI]: 0.58–0.93) for well and moderately differentiated versus poorly differentiated tumors, 0.65 (95% CI: 0.45–0.94) for T1/T2 versus T3/ T4 tumors, 0.59 (95% CI: 0.39–0.90) for N0 versus N1 tumors, and 0.48 (95% CI: 0.33–0.71) for stage I/II versus stage III/IV diseases, respectively. The association between cyclin D1 expression and prognosis was examined in 10 studies, and the combined hazard ratio was 1.78 (95% CI: 1.49–2.12). Cyclin D1 expression level detected by IHC is associated with worst clinicopathological features and prognosis for ESCC.